SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. Show more

Location: 31 East 62nd Street, New York, NY, 10065, United States | Website: https://www.siga.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare

Market Cap

643.7M

52 Wk Range

$4.95 - $9.62

Previous Close

$8.99

Open

$9.00

Volume

436,392

Day Range

$8.56 - $9.03

Enterprise Value

461.8M

Cash

182.5M

Avg Qtr Burn

N/A

Insider Ownership

43.24%

Institutional Own.

50.33%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TPOXX (Intravenous) Details Smallpox, Vaccine	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TPOXX® (tecovirimat) Details Smallpox	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.